Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Head and Neck Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Head and Neck Neoplasm

Cancer Family

Head and Neck Neoplasm

CI-CAN-00000021Explore in graph →

Non-malignant1,572 active trials17 approved drugs142 evidence items

NCIt: C3077
MeSH: D006258

Overview
Statistics
Survival
Genomics28
Variants & evidence142
Drugs54
Trials6373
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (373)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 251–275 of 373 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
· Lancet Diabetes Endocrinol · 2021 · PMID 34118198 · validated civic_curation pubmed
Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
· Horm Metab Res · 2014 · PMID 24570209 · validated civic_curation pubmed
The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
· Clin Endocrinol (Oxf) · 2014 · PMID 24354346 · validated civic_curation pubmed
BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
· J Clin Oncol · 2014 · PMID 25024077 · validated civic_curation pubmed
Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.
· Int J Exp Pathol · 2005 · PMID 16309541 · validated civic_curation pubmed
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
· J Clin Invest · 2005 · PMID 15630448 · validated civic_curation pubmed
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.
· J Clin Oncol · 2007 · PMID 17538160

Showing 251–275 of 373 publications

← Previous
1
…
10
11
12
…
15
Next →

· validated civic_curation

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

· J Clin Oncol · 2006 · PMID 16943533 · validated civic_curation pubmed

TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.

· Radiother Oncol · 2001 · PMID 11325447 · validated civic_curation pubmed

Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.

· Clin Cancer Res · 2011 · PMID 21467160 · validated civic_curation pubmed

Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma.

· Oral Oncol · 2003 · PMID 12509970 · validated civic_curation pubmed

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.

· Ann Oncol · 2011 · PMID 21048039 · validated civic_curation pubmed

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.

· Eur J Cancer · 2013 · PMID 23265711 · validated civic_curation pubmed

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.

· Ann Oncol · 2014 · PMID 24799460 · validated civic_curation pubmed

Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.

· Cell Death Dis · 2014 · PMID 24577089 · validated civic_curation pubmed

Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.

· J Clin Oncol · 2016 · PMID 26712222 · validated civic_curation pubmed

Elevated Serum Gas6 Is a Novel Prognostic Biomarker in Patients with Oral Squamous Cell Carcinoma.

· PLoS One · 2015 · PMID 26207647 · validated civic_curation pubmed

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.

· J Clin Endocrinol Metab · 2008 · PMID 18682506 · validated civic_curation pubmed

When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?

· Ann Surg Oncol · 2009 · PMID 19472011 · validated civic_curation pubmed

Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.

· Clin Cancer Res · 2017 · PMID 28476872 · validated civic_curation pubmed

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Retracted

· N Engl J Med · 2015 · PMID 26287849 · validated civic_curation pubmed

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

· J Clin Oncol · 2018 · PMID 29320312 · validated civic_curation pubmed

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

· J Clin Oncol · 2018 · PMID 29072975 · validated civic_curation pubmed

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.

· Cancer · 2016 · PMID 27525386 · validated civic_curation pubmed

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

· Lancet Oncol · 2016 · PMID 27460442 · validated civic_curation pubmed